AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer
2024年5月8日 - 10:14PM
ビジネスワイヤ(英語)
AdvanCell, a clinical-stage radiopharmaceutical company
developing a pipeline of Targeted Alpha Therapies for patients with
cancer, today announced the appointment of two senior management
team members.
Chris Horvath, MS, MBA - Chief Commercial and Operating Officer
based in Philadelphia. Chris brings nearly two decades of
biopharmaceutical oncology expertise spanning drug discovery,
commercialization, and corporate leadership, to AdvanCell. Over the
past eight years, Chris has been responsible for commercial
strategy and leadership, launch preparation and execution, and
revenue growth of both clinical-stage and commercial
radiopharmaceuticals in oncology. Most recently, at POINT
Biopharma, he served as EVP, Commercial and managed
cross-functional alliance operations with Lantheus for two
clinical-stage assets. As head of the prostate cancer franchise at
Novartis/Advanced Accelerator Applications, Chris orchestrated the
organizational build and set the strategic foundation for the
successful US launches of Pluvicto and Locametz. Prior to this,
Chris held progressively senior commercial positions at Janssen,
Dendreon, Merck, and Bayer.
Gary Li, PhD - Chief Strategy Officer based in San Diego. Gary
has over 20 years of multi-modality drug discovery, translational,
and early development experience at both the strategic and
operational levels. Most recently, as RayzeBio’s 3rd employee and
SVP, Gary led Discovery Biology, Translational Medicine, and
Portfolio Strategy. Gary spearheaded the effort to establish a rich
portfolio from novel targets to Phase III assets. In addition, he
played a key role in company building, fundraising, licensing, and
scientific communication. Before joining RayzeBio, Dr. Li was SVP,
Translational Medicine at BridgeBio, VP of Oncology Research at
Ignyta, and held various scientific positions with increasing
responsibilities at Pfizer and Johnson & Johnson, contributing
to target ID/validation, drug discovery and multiple drug
approvals. Gary is an inventor on multiple patents, has published
over 50 peer-reviewed articles, and delivered over 100 invited
talks and meeting presentations.
“I am excited to have Chris and Gary join our efforts to
discover, develop and commercialize innovative
radiopharmaceuticals,” said Andrew Adamovich, CEO of AdvanCell.
“Their expertise will fuel our innovation, their leadership will
help guide our journey, and together, we will pioneer breakthroughs
that will change the course of cancer treatment.”
Chris and Gary join a growing North American Senior Management
Team which includes:
- Anna Karmann, MD, PhD – Chief Medical Officer
- Matthew Vincent, JD, PhD – Chief Business Officer
- Michael Tung, MD, MBA – Chief Financial Officer
- Amanda Walker, MD - VP Regulatory Affairs & Late-Stage
Development
- Alyssa Vito, PhD - Associate Vice President Clinical
Development
About AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company
developing an innovative pipeline of Targeted Alpha Therapies for
patients with cancer. AdvanCell’s platform technology addresses the
most significant challenge in targeted alpha therapy – the reliable
and scalable supply of isotope. AdvanCell’s novel drug discovery,
preclinical processes, and state-of-the-art facilities leverage
daily access to 212Pb, the ideal isotope for Targeted Alpha
Therapy. For more information, please visit
www.advancell.com.au
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240508288002/en/
Investors or Media contact@advancell.com.au